Levetiracetam
Product Images NDC 50090-5760

8 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-5760). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500905760)

Label Image (Lbl500905760)
Levetiracetam 500 mg film-coated tablets label from A-S Medication Solutions. It includes the product name and strength, storage instructions to keep between 68 to 77 degrees Fahrenheit, package size of 32 unit dose tablets, and the product NDC 50090-5760-0. Also shown is a QR code linked to dosage information.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' displaying the percentage of patients achieving this endpoint. It compares placebo (7.4%, N=95), levetiracetam 1000 mg/day (37.1%, N=97), and levetiracetam 3000 mg/day (39.6%, N=101). Statistically significant differences versus placebo are marked with an asterisk.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
A bar chart showing responder rates (≥50% reduction from baseline) in Study 2: Period A for Levetiracetam. The chart compares placebo (6.3%), Levetiracetam 1000 mg/day (20.8%), and Levetiracetam 2000 mg/day (35.2%) with patient counts noted for each group. Statistically significant differences versus placebo are marked with an asterisk.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing the percentage of patients responding to placebo versus Levetiracetam 3000 mg/day. The chart shows approximately 14.4% response rate for placebo (N=104) and 39.4% for Levetiracetam (N=180), with an asterisk indicating statistically significant difference versus placebo.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
A bar chart titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing the percentage of patients responding to Placebo and Levetiracetam. The graph shows 19.6% response for Placebo (N=97) and a higher 44.6% response for Levetiracetam (N=101), with the difference marked as statistically significant versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
Bar graph showing the responder rate for patients aged 1 month to under 4 years with at least 50% reduction from baseline in Study 5. The graph compares Placebo (19.6% response rate, N=51) to Levetiracetam (43.1% response rate, N=58) with asterisks indicating statistical significance versus placebo.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
Bar chart showing responder rates (≥50% reduction from baseline) in PGTC seizure frequency per week in Study 7, comparing Placebo and Levetiracetam groups. The y-axis represents the percentage of patients, with Placebo at 45.2% and Levetiracetam at 72.2%, indicating statistical significance favoring Levetiracetam.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)
Chemical structure of levetiracetam, showing a 2-oxo-pyrrolidine ring attached to an ethyl group and an amide group. The diagram uses standard organic chemistry notation for bonds and atoms.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.